Introduction
1,25-Dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), the active metabolite of vitamin D, exerts anti-cancer activities by binding to the vitamin D receptor (VDR) and modulating gene expression [1] . Historically, the anti-tumor activity of 1,25(OH) 2 D 3 has been attributed largely to its ability to suppress cell cycle progression via the induction of cyclin dependent kinase inhibitors p21 waf1 and p27 kip1 [2] [3] [4] [5] [6] .
However, more recent studies demonstrate that 1,25(OH) 2 D 3 inhibits a number of additional processes critical to tumor survival and progression including angiogenesis [7] [8] [9] , telomerase activation [10, 11] , and the epithelial-mesenchymal transition (EMT) [12] [13] [14] [15] . EMT refers to a process in which cells lose expression of genes associated with an epithelial phenotype (such as E-cadherin (CDH1)) and acquire expression of genes associated with a mesenchymal phenotype (such as vimentin (VIM)). Transcription factors belonging to the SNAIL and ZEB families coordinate EMT by repressing CDH1 and other cell junction proteins (reviewed in [16] ). EMT-associated changes in gene expression are accompanied by alterations in cell morphology and behavior, such that cells which have undergone EMT acquire an elongated, spindle shape and display increased migration and invasiveness.
In lung cancer models, EMT confers resistance to both radiation and chemotherapy [17, 18] . EMT also determines the therapeutic response of NSCLC cells to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib. In 2005 it was discovered that NSCLC cells with wild-type EGFR display a range of sensitivities to erlotinib, and that sensitivity depends on whether the cells express CDH1 or VIM [19] . Consistent with these findings, CDH1 transfection was demonstrated to be sufficient to sensitize NSCLC cells to EGFR tyrosine kinase inhibitors [20] . At the same time, microarray approaches were used to uncover the basis for the differential responsiveness of NSCLC cells to erlotinib. These also resulted in the identification of EMT as a determinant of drug sensitivity and CDH1 protein expression as a biomarker of erlotinib activity in NSCLC patients [21] . EMT also represents an important mechanism by which NSCLC cells and NSCLC patients become resistant to EGFR tyrosine kinase inhibitors during treatment [22] .
To more fully characterize EMT in NSCLC and its association with drug response, Byers et al. recently developed and validated a 76-gene EMT signature: This signature predicts the resistance of NSCLC cells to EGFR and PI3K inhibitors and disease control in NSCLC patients receiving erlotinib [23] . Several of the NSCLC cell lines that were used in the derivation of the EMT signature were previously characterized for their sensitivity towards 1,25(OH) 2 D 3 by us [24] . This afforded us the unique opportunity to explore the relationship between vitamin D signaling capacity and the EMT phenotype in NSCLC. Data contained in this report provide initial evidence that the EMT phenotype (as defined by the 76-gene EMT signature) discriminates between NSCLC cells that are sensitive or resistant to the growth inhibitory effects of 1,25(OH) 2 D 3 , and that the epithelial phenotype is actively supported by 1,25(OH) 2 D 3 . The implications of these findings with regard to the clinical application of vitamin D in the treatment of NSCLC are provided in the Discussion.
Results and Discussion
A 76-gene signature which classifies whether a NSCLC cell line has undergone EMT was recently described by Byers et al. [23] . Hierarchical clustering of 54 NSCLC cell lines based on the 76-gene signature resulted in distinct epithelial and mesencyhmal groups. Upon examining the cell lines that fell within each group, we noted a possible association between EMT phenotype and 1,25(OH) 2 (10 nM) , as outlined in the Experimental section. * Value was abstracted from previously published work [24, 25] . The EMT phenotype was defined by Byers et al based on a 76-gene signature [23] . E (epithelial), M (mesenchymal), ND (not determined). 
VDR

Characterization of the Association between Vitamin D Signaling Capacity and EMT Phenotype in NSCLC Cells
Based on our initial observations described above, we hypothesized that EMT phenotype distinguishes between cells that express the VDR and are vitamin D-sensitive and those that weakly express VDR and are vitamin D-refractory. To test this, two approaches were taken. First, qRT-PCR was used to measure the expression of epithelial markers (CDH1, SCNN1A, and EPCAM) and mesenchymal markers (ZEB1, VIM, LIX1L) across the full set of NSCLC cell lines for which we had vitamin D sensitivity data (presented in Table 1 To confirm that the RNA-based signatures were reflected in expression of corresponding proteins, whole cell extracts were prepared from each of the cell lines and examined for expression of VDR, E-cadherin, and VIM by immunoblot. H3122, H292 and HCC827 cells that were classified as VDR high and epithelial based on their RNA expression profiles displayed high expression of VDR, high expression of E-cadherin, and were VIM negative ( Figure 1B) . Conversely, H23, A427, and A549 cells that were classified as VDR low and mesenchymal based on their RNA expression profiles displayed little to no VDR, little to no E-cadherin, and high levels of VIM. Furthermore, as predicted from the RNA data, SK-LU-1 cells expressed VDR but had undetectable levels of either E-cadherin or VIM. These data indicate high concordance between RNA and protein based EMT markers. In a second approach, we determined the correlation between expression of VDR and genes included in the 76-gene EMT signature of Byers et al. using publically available GEO dataset GSE4824. Probes for only 48 of the EMT signature genes were contained within the array data. Therefore, these 48 genes were surveyed. GSE4824 includes samples from >75 lung cancer cell lines and was used in derivation of the EMT gene signature [23] . The gene most inversely related to VDR was the mesenchymal marker ZEB1, with a correlation coefficient of −0.385. The three genes which showed the strongest positive correlation with VDR were TACSTD2, SH3YL1 and the epithelial marker, CDH1 (correlation coefficients between 0.73-0.77). TACSTD2 and SH3YL1 appear to mark cells with a more epithelial phenotype, as their expression correlates positively with CDH1 and negatively with VIM [23] . The complete ranked gene-by-gene analysis is provided in Table 2 . These results are consistent with our cell line experiments and support an association between VDR expression and EMT phenotype in NSCLC cells. 
Analysis of the Effects of 1,25(OH) 2 D 3 on EMT Related Genes and Migration of SK-LU-1 cells
Cumulatively, the above data suggest that NSCLC cells with an epithelial gene signature have higher expression of VDR and greater sensitivity to 1,25(OH) 2 D 3 treatment than cells with a mesenchymal phenotype. VDR/1,25(OH) 2 D 3 signaling has been shown to influence the EMT in rat lung epithelial cells and in breast and colon cancer cells [12, 14, 26] . Therefore, we next sought to determine whether in NSCLC cells 1,25(OH) 2 D 3 actively supports the epithelial phenotype or is simply correlated with it. To do this, we treated SK-LU-1 cells with vehicle or increasing concentrations of 1,25(OH) 2 D 3 . After 96h, RNA was isolated and the expression of CDH1, VIM, and ZEB1 was measured by qRT-PCR. SK-LU-1 cells were used for these studies because they had an intermediate EMT phenotype and retained VDR expression (Figure 2A inset) and so might be susceptible to regulation by 1,25(OH) 2 D 3 . Indicative of an active role for 1,25(OH) 2 D 3 in regulation of the EMT in SK-LU-1, treatment resulted in a 2.6-fold increase in CDH1 expression and a modest 30%-50% decrease in expression of both VIM and ZEB1 (Figure 2A ).
To ascertain whether such changes in gene expression might have functional relevance, we subsequently evaluated the effect of 1,25(OH) 2 (Table 1) . Based on our prior work in NSCLC cells, CYP24A1 induction was expected to result in a time-dependent decline in 1,25(OH) 2 D 3 levels [27] . To avoid the need for periodic replenishment of 1,25(OH) 2 D 3 and minimize disruption of the cell monolayers during the migration assays, the CYP24A1 selective inhibitor, CTA091 was added in combination with 1,25(OH) 2 D 3 . CTA091 itself had no effect on cell migration at any of the time points examined ( Figure 2B ). In contrast, treatment of SK-LU-1 cells with 1,25(OH) 2 D 3 plus CTA091 for 48 h or greater resulted in significant inhibition of cell migration. (B) SK-LU-1 cells were seeded into ibid cell culture inserts as outlined in the Experimental Section. The next day, the inserts were removed, and cells were treated with fresh medium containing vehicle (controls), CTA091 (50 nM), or 100 nM 1,25(OH) 2 D 3 plus CTA091 (50 nM). The number of cells that migrated into the open field at various times post-treatment (h) was determined. Migration was measured at three locations within each well, and the data from 3 independent experiments (1−3 wells/experiment) was pooled. Each data point reflects a separate measurement, and horizontal bars indicate the mean cell number. Data were analyzed for statistical significance using an unpaired t-test.
Analysis of the Effects of 1,25(OH) 2 D 3 on TGFβ Induction of the EMT in VDR high NSCLC cells
TGFβ treatment induces EMT in epithelial cells (reviewed in [28] ). Therefore, as a further test of the effect of 1,25(OH) 2 To determine whether changes in RNA expression resulted in corresponding changes in protein expression, HCC827 cells were treated and then analyzed for expression of E-cadherin and VIM by immunofluorescence. Untreated H292 (E-cadherin positive, VIM negative) and A549 cells (E-cadherin low, VIM positive) were included as staining controls. Consistent with the RNA-based data, TGF treatment resulted in a decrease in E-cadherin expression in at least some cells (unstained cells indicated with white arrow in Figure 3C ) and bright focal expression of VIM (example shown with white arrows in Figure 3C ). These same bright foci were observed following VIM staining of control A549 cells but not H292 cells, indicating they are VIM specific. Conversely, 1,25(OH) 2 D 3 -treated cells displayed bright E-cadherin staining at the plasma membrane and close connectivity between cells. Cells treated with the combination of 1,25(OH) 2 D 3 plus TGF had a staining pattern that was generally consistent with 1,25(OH) 2 D 3 alone: both E-cadherin positive cell clusters and an absence of VIM bright foci were noted. We conclude from these morphological observations, gene expression profiles, and immunofluorescence data that the ability of TGFβ to induce an EMT in HCC827 cells is attenuated in the presence of 1,25(OH) 2 D 3 .
Discussion
Recently, a 76-gene signature was defined which distinguishes NSCLC cells based on their EMT phenotype and predicts resistance of NSCLCs to EGFR and PI3K inhibitors [23] . We build upon these findings and show that EMT phenotype (as predicted by the 76-gene EMT signature) also appears to predict resistance to vitamin D. We demonstrate that NSCLC cells which are characterized as epithelial based on the EMT signature express VDR and are sensitive to 1,25(OH) 2 (Figure 1 , Table 1 ). One limitation in arriving at this conclusion is that we characterized the relationship between EMT phenotype and 1,25(OH) 2 D 3 sensitivity in a relatively small number of cell lines using only a subset of genes derived from the EMT signature. To circumvent this limitation, we examined the relationship between VDR and 48 genes derived from the 76 gene EMT signature using a publically available dataset containing gene expression profiles from >75 lung cancer cell lines. Using this approach, we uncovered a positive association between VDR and CDH1 and a negative association between VDR and ZEB1. We believe that the results of this microarray analysis support our laboratory observations and increase the likelihood that our findings regarding EMT phenotype and 1,25(OH) 2 D 3 sensitivity are relevant and can be generalized. We know from prior work by us and others that VDR expression predicts the response of NSCLC cells to 1,25(OH) 2 D 3 treatment [24, 29, 30] . Thus, one implication of our current work is that an EMT signature may be useful in identifying the subset of NSCLC patients with VDR high /vitamin D responsive tumors.
1,25(OH) 2 D 3 Opposes EMT Induction in NSCLC Cells
In HCC827 cells, TGFβ induces expression of SNAIL and ZEB1, master transcriptional regulators of the EMT. When TGFβ is combined with 1,25(OH) 2 D 3 , its ability to increase SNAIL and ZEB1 expression is reduced. These data lead us to conclude that 1,25(OH) 2 D 3 signaling opposes EMT induction by TGFβ. 1,25(OH) 2 D 3 also down-regulates expression of SNAIL and ZEB1 and opposes EMT induction in colon cancer cells [12, 13] . The mechanistic details of the vitamin D/EMT regulatory circuit in colon cancer cells have been defined: 1,25(OH) 2 D 3 increases expression of the histone demethylase KDM6B/JMJD3 [12] . In turn, JMJD3 controls expression of miR-200b and miR-200c, which target ZEB1 for degradation [13] . We are currently investigating the contribution of this mechanism towards vitamin D control of the EMT in NSCLC cells.
EMT Signature may Identify NSCLC Patients that Benefit from 1,25(OH) 2 D 3 Treatment
The finding of a relationship between vitamin D signaling capacity and EMT phenotype has important implications for lung cancer treatment and progression. Improvements in the treatment of advanced NSCLC have arisen from the molecular phenotyping of tumor cells and application of appropriate molecularly targeted therapies. For example, response to the EGFR tyrosine kinase inhibitor, erlotinib, is approximately 10% in an unselected population of patients with advanced NSCLC, but it is nearly 70% in those individuals whose lung tumors harbor activating mutations in EGFR (reviewed in [31] ). To date, no gene signature has been available to identify a population of NSCLC patients that may benefit from 1,25(OH) 2 D 3 supplementation. Based on our novel finding that a relationship exists between vitamin D sensitivity and EMT phenotype, we hypothesize that an EMT signature such as the one described by Byers et al. may prove to be clinically useful in identifying a responsive patient subset. Furthermore, our data lead us to predict that vitamin D supplementation will be effective selectively in NSCLC patients whose tumors are identified as being epithelial based on the EMT signature.
With regard to the identification of molecularly-defined lung cancer subsets that respond preferentially to vitamin D, we previously reported that NSCLC cells with activating EGFR mutations expressed high levels of VDR and were 1,25(OH) 2 D 3 sensitive whereas NSCLC cells with oncogenic K-ras mutations were VDR-deficient and 1,25(OH) 2 D 3 -refractory [24] . When the 76-gene EMT signature was applied to 54 NSCLC cell lines, Byers et al. observed that all nine EGFR mutant cell lines included in their study had an epithelial phenotype. Conversely, K-ras mutations were more common in cell lines with a mesenchymal phenotype [23] . Thus, our results regarding the relationship between (a) oncogene mutations and vitamin D signaling capacity and (b) EMT status and vitamin D signaling capacity are concordant. In light of our new data, we speculate that the basis for the prior association we noted between oncogenic mutations and vitamin D sensitivity may not have resulted from a specific effect of the mutations on vitamin D signaling capacity per se. Rather, these mutations may drive the NSCLC cells into a particular biological state (EGFR mutation/epithelial state or K-ras mutation/mesenchymal state) in which vitamin D responsiveness is altered. The precise mechanism by which vitamin D signaling becomes silenced as lung cancer cells acquire a mesenchymal phenotype remains to be determined. One possibility is that the EMT transcriptional regulator SNAIL binds to the VDR promoter and represses its transcription [32] .
Experimental
Cell Culture
HCC827, H23, A427, SK-LU-1, H3122, H292 and A549 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). A549 cells were cultured in BME medium supplemented with 2 mM glutamine (Life Technologies, Grand Island, NY, USA). HCC827, H23, H3122, and H292 cells were cultured in RPMI 1640 containing 2 mM glutamine (Corning, Tewksbury, MA, USA). H292 cells received additional supplementation with 1mM sodium pyruvate and 10 mM HEPES buffer. SK-LU-1 and A427 cells were cultured in EMEM containing 2 mM glutamine (ATCC). Unless otherwise specified, all media preparations contained 10% fetal bovine serum (FBS, Tissue Culture Biologicals, Tulare, CA, USA) and 100 U/mL penicillin-streptomycin. Cells were incubated at 37 °C with 5% CO 2 . All cells were periodically tested for mycoplasma and consistently found to be negative. No cells were used for experimental studies beyond 25 passages in our laboratory.
Reagents and Chemicals
The vitamin D metabolite, 1,25(OH) 2 D 3 , was generously provided as a 480 μM stock in absolute ethanol by Dr. Candace Johnson (Roswell Park Cancer Institute, Buffalo, NY, USA). Immediately prior to use, the stock was diluted to a final concentration of 10 or 100 nM in fresh tissue culture medium. Recombinant human TGFβ1 (R&D Systems, Inc. Minneapolis, MN, USA) was prepared as a stock of 20 ng/µL in 4 mM HCl containing 0.5% BSA. Immediately prior to use, it was diluted in fresh tissue culture media to a final concentration of 0.125 ng/mL. For studies involving TGFβ1, the treatments were replenished every two days. CTA091 was kindly provided by Cytochroma, Inc (Markham, ON, Canada). It was diluted and handled as described previously [24] .
RNA Isolation
For EMT studies, cells were seeded in six well plates at a density of 5 × 10 3 cells per well and were treated with either vehicle control, 1,25(OH) 2 D 3 , 0.125 ng/mL TGFβ1, or the combination of TGFβ1 and 1,25(OH) 2 D 3 . Treatments were replenished every two days for a total of four treatments. Four hours following the last treatment, cells were collected in TRI-reagent (Direct-Zol RNA Mini-Prep Kit, Zymo Research, Irvine, CA, USA) to initiate RNA extraction. RNA isolation was carried out per manufacturer's instructions. RNA concentrations were read using a NanoDrop. All RNA had a 260/280 ratio of at least 2. Eluted RNA was stored at −80 °C until further use.
cDNA Synthesis
500 ng of RNA was converted to cDNA using a High Capacity cDNA Reverse Transcription Kit, which included an RNase inhibitor (Applied Biosystems, Foster City, CA, USA). A 20 μL reaction was prepared, and cDNA synthesis was carried out following the manufacturer's instructions.
Real-Time PCR
Real-time PCR reactions were prepared using the Maxima SYBR green/ROX qPCR Master Mix (Thermo Scientific, Pittsburgh, PA, USA) and run on a 7300 Real Time PCR System (Applied Biosystems). A volume of 1 μL of cDNA was added per reaction. The reactions were run at 50 °C for 2 min, 95 °C for 10 min, and then subjected to 40 cycles of 95 °C for 20 s, 56 °C for 25 s and 72 °C for 27 s. Data was collected during the 72 °C extension step. Relative gene expression was calculated using the 2 −ΔΔCt method. All primers were purchased from Integrated DNA Technologies. Primer sequences are as follows (F: forward; R: reverse) in Table 3 . 
Clonogenic Assay
Cells were seeded in triplicate wells in complete growth medium at a density optimized for each cell line. Cells were treated with either vehicle control or 1,25(OH) 2 D 3 every two days for 10 days. At the time of harvest, colonies were fixed by adding 2 mL of 70% methanol per well for 5 min. This step was repeated, and the colonies were then stained using 2 mL of 0.1% crystal violet for 5 min. Wells were rinsed with water and dried for 24 h prior to quantitation. Colonies were inspected microscopically, and a colony was defined as a cluster of at least 30 cells. To calculate the percent colonies remaining, the following equation was used: % colonies remaining = 100 × [number colonies for treatment group/average number colonies for control group].
Migration Assay
SK-LU-1 cells were trypsinized and resuspended in complete tissue culture medium to a concentration of 2 × 10 5 cells/mL. One cell culture migration insert (ibidi, Verona, WI, USA) was placed into one well of a six-well plate. A volume of 70 μL of the cell suspension was placed into each side of the insert. The next day, the inserts were removed, and 2 mL of treatment medium was added.
Treatments included vehicle control, 1,25(OH) 2 D 3 , CTA091 or the combination of 1,25(OH) 2 D 3 plus CTA091. Pictures were taken each day from the time the inserts were removed until study termination using a Leica DMIL microscope equipped with a Leica ICC50 HD camera. Three images were taken per culture insert in the left, middle, and right viewing fields and were quantified by counting the number of cells that migrated into the open field. Each image was treated as a separate measurement.
Preparation of Whole Cell Extracts and Immunoblotting
Protein extraction and immunoblotting was done as described by us previously [24] . The following primary antibodies were used: mouse anti-human E-cadherin, clone 36 (BD Transduction Laboratories, San Jose, CA, USA); mouse anti-human Vimentin, clone RV202 (BD Pharmingen, San Diego, CA, USA); rat anti-VDR, clone 9A7 (Thermo Scientific, Rockford, IL, USA), and rabbit anti-actin (sc-1616-R, Santa Cruz Biotechnology, Dallas, TX, USA). Antibodies against E-cadherin, Vimentin, and VDR were used at a dilution of 1:1,000. Anti-actin antibody was used at a dilution of 1:2,000.
Immunofluorescence
Cells were seeded onto sterile coverslips at a density of 5 × 10 3 /well. were diluted in 1% BSA and exposed to the cells overnight. The next day, the cells were washed, stained with DAPI, and mounted to microscope slides (Molecular Probes, Invitrogen, Grand Island, NY, USA). Images were taken using QCapture software.
Microarray Analysis
Gene expression profiles of NSCLC cells along with their annotation were downloaded from NCBI's Gene Expression Omnibus repository (GSE4824) [33] . The Epithelial-Mesenchymal Transition (EMT) gene signature was obtained from [1] . The expression values of the VDR gene (probe 204254_s_at) and the EMT signature genes were extracted and the correlation between VDR and each of the EMT signature genes was calculated and ranked. The analysis was performed using the statistical computational environment R Version 2.15.2 [34] .
GSE4824 contains 164 samples, with 6 samples profiled by the Affymetrix Plus2.0 platform, 79 samples profiled by the Affymetrix U133A platform, and 79 samples profiled by the Affymetrix U133B platform. Since there are no VDR probes in the U133B platform, the 79 samples profiled by the Affymetrix U133B platform were discarded. The EMT gene signature contains 96 Affymetrix probes for 76 genes. Because 42 probes were not in the U133A platform, we discarded them from the analysis. Hence, our final analysis included 54 probes (from 48 unique genes) which are available in both the Affymetrix Plus2.0 and U133A platforms.
Conclusions
Studies presented in this manuscript provide evidence that (A) a relationship exists between EMT phenotype and vitamin D sensitivity in NSCLC and that (B) 1,25(OH) 2 D 3 actively suppresses EMT in at least some NSCLC cells. These results have two important clinical implications. First, as noted above, our work suggests that an EMT signature may be useful in identifying the subset of NSCLC patients with VDR high /vitamin D responsive tumors. In lung cancer, the EMT is associated with increased tumor cell proliferation, invasion, migration, metastasis, and chemotherapy resistance [17, 18, 35, 36] . Thus, the second implication of our work is that by suppressing EMT, 1,25(OH) 2 D 3 may prevent or reduce the onset of metastatic disease, may enhance response to chemotherapy, or may delay the development of resistance to conventional chemotherapy and molecularly targeted agents. The effect on EMT, combined with the documented ability of 1,25(OH) 2 D 3 to directly suppress the growth of NSCLC cells via cell cycle inhibition [25, 29] , provides a reasonable explanation for the observed favorable association between vitamin D status and better outcomes in NSCLC [37, 38] .
